Why the study?
Ultra-low temperature cryoablation was developed to combine the effectiveness of surgical lesion delivery with percutaneous safety to improve catheter ablation outcomes in atrial fibrillation, especially persistent AF.
Does ultra-low temperature cryoablation (ULTC) provide safety and efficacy (freedom from AF) in patients with atrial fibrillation?
Does ultra-low temperature cryoablation (ULTC) provide safety and efficacy (freedom from AF) in patients with atrial fibrillation?
Ultra-low temperature cryoablation is a novel modality that demonstrated 85.9% 1-year freedom from AF in persistent AF patients, supporting further clinical evaluation.
Should not yet change ablation practice in persistent AF; leaves open comparative efficacy pending randomized trials.
Ultra-low temperature cryoablation (ULTC) is a novel ablation modality aiming to combine the effectiveness of surgical lesion delivery with percutaneous safety to improve outcomes in catheter ablations of atrial fibrillation, particularly in persistent AF (PsAF). In the Cryocure-2 study (NCT02839304) 78 patients (56.4% PsAF) received ULTC pulmonary vein isolation plus posterior wall ablation, and linear left and right atrial lesions as needed. The safety and acute success of ULTC appear consistent with current catheter ablation techniques and, together with Kaplan-Meier 85.9% 1-year freedom from AF observed in Cryocure-2 PsAF patients, warrant further evaluation in larger clinical trials, which are currently ongoing.
No takes yet. Share an insight, caveat, or question.
Potter et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: